1
Bibliografia
1) Arvind S. Negi , Jonnala K. Kumar, Suaib Luqman, Dharmendra Saikia , and
Suman P.S. Khanuja ; “Antitubercular Potential of Plants : A Brief Account of
Some Important Molecules”; Medicinal Research Reviews 2009 Wiley
Periodicals.
2) L.J. McGaw, N. Lall, J.J.M. Meyer, J.N. Eloff ; “The potential of South
African plants against Mycobacterium infections” ; Journal of
Ethnopharmacology 119 (2008) 482-500.
3) Charles L. Cantrell , Scott G. Franzblau , Nikolas H. Fisher ;
“Antimycobacterial Plant Terpenoid”; Planta Med 67 (2001) 685-694.
4) Walter e M.S. Israel ; “ Patologia generale” ; Edizione italiana a cura di
Alberto Fannesu ; E.M.S.I. –Edizione mediche scientifiche internazionali- Roma 1977.
5) Sandra M. Newton , Clara Lau and Colin W. Wright ; “Review of
antimycobacterial natural products” ; John Wiley & Sons, Ltd.
6) Bertram G. Katzung ; “Farmaci antimicobatterici”, “Farmcologia generale e
clinica” ; Piccin, cap. 47, 845-853.
7) Helen Mc Shame ; “Vaccine strategies against tuberculosis” ; The Jenner
Institute University of Oxford, United Kingdom ; Swiss Med WKLY 2009 139 (11-12).
8) Anna Milano, Maria Rosalia Pasca , Roberta Provvedi , Ana Luisa de Jesus
Lopes Ribeiro , Riccardo Mangawelli , Giovanna Riccardi ; “Azole Resistance
in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system” ; Tuberculosis 89 (2009) 84-90.
9) Ruirushi , Nobunori Itagaki and Isamu Sugawara ; “Overview of
Anti-tuberculosis (TB) Drugs and their Resistance Mechanisms” ; Mini-Reviews in Medicinal Chemistry, 2007,7,1177-1185.
2
10) Vadim Makarow e al. ; “Benzothiazinones kill Mycobacterium tuberculosis by
blocking Arabinan synthesis” ; Science vol. 234 8 May 2009.
11) “Scoperto nuovo farmaco contro la tubercolosi (23/04)” ; http: // italiasalute.leonardo.it /News.Asp?ID=10059.
12) “TBC : nuovo test per l’identificazione” ; http: // italiasalute.leonardo.it/News. Asp? ID=10059.
13) Stop TB Partnership ; “The Global Plan to Stop TB”;2006.
14) WHO; Global tuberculosis control ; “Surveillance,plaining and
financing”;WHO report ; WHO, Geneva, Switzerland 1-247, 2005:1-247.
15) Fine PC, IAM ; Milstein JB, Clements CJ ; “Issues relating to the use of BCG
in immunization programmes”; WHO, Geneva , 1999.
16) Rodrigues LC, Diwan VK, Wheeler JG ; “Protective effect of BCG against
tuberculosis meningitis and military tuberculosis :a meta-analysis” ; Int J
Epidemiol, 1933, 22 (6):1154-8.
17) Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al.; “Efficacy of BCG vaccine in the prevention of tuberculosis” ; Meta-analysis of the published literature ; JAMA, 1994, 271 (9):698-702.
18) Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichiara MY, de Brito SC, et al.; “Effect of BCG revaccination on incidence of tuberculosis in school-aged
children in Brazil: the BCG-REVAC cluster-randomised trial”; Lancet, 2005,
366(9493):1290-5.
19) Epstein PR ; “BCG vaccination and nutrition”; Lancet, 1990, 335 (8704):1536-7.
20) Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, et al.;
“BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK :two randomized controlled studies”; Lancet, 2002, 359 (9315):1393-401.
21) Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, et al.; “Failure of the Mycobacterium bovis BCG vaccine:some species of
3
environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis”; Infect Immun, 2002, 70 (2):672-8.
22) Blanchard TJ, Alcamin A, Andrea P, Smith GL; “Modified vaccinia virus
Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:implications for use as a human vaccine”; J Gen
Virol, 1998, 79 (Pt5):1159-67.
23) D’Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, et al.;
“Mapping of murine Th1 helper T-Cell epitopes of micolyl transferases Ag85A,Ag85B, and Ag85C from Mycobacterium tuberculosis”; Infect Immun,
2003, 71 (1):483-93.
24) Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, et al.; “Immunogenicity and protective efficacy of a tuberculosis DNA vaccine”; Nat. Med. 1996, 2 (8):893-8.
25) Pai M, Riley LW, Colford JM Jr; “Interferon-gamma assays in the
immunodiagnosis of tuberculosis : a systematic review”; Lancet Infect Dis,
2004, 4 (12):761-76.
26) Mc Shane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV;
“Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials”; Tuberculosis (Edinb.), 2005, 85 (1-2):47-52.
27) Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM;
“Pulmonary necrosis resulting from DNA vaccination against tuberculosis”;
Infect Immun, 2003, 71 (4):2192-8.
28) Koch R; “Forsetzung der Mittelungen uber ein Heimittel gegen
Tuberkulose”; Dtsch Med Wochenschr, 1891, 17:101-2.
29) Keating SM, Mc Shane H, Pathan AA, Sander CR, Gilbert SC, Huygen K, et al.; “Recombinant modified vaccinia virus Ankara expressing antigen 85A
boots BCG-primed and naturally acquired antimycobacterial immunity in humans”; Nat Med, 2004, 10(11):1240-4.
4
al.; “Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing
Antigen 85A:Different Boosting Intervals and Implications for Efficacy Trials”; PLoS ONE, 2007, 2(10):e1052.
31) Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al.;
“Safety and immunogenicity of a new tuberculosis vaccine,MVA85A,in healthy adults in South Africa”; J Infect Dis., 2008, 198(4):544-52.
32) McLean KJ, Dunford AJ, Neeli R, Driscoll MD, Munro AW;
“Structure,function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems”; Arch Biochem Biophys, 2007, 464:228-40.
33) Ahmad Z, Sharma S, Khuller GK; “Azole antifungals as novel
chemotherapeutic agents against murine tuberculosis”; FEMS Microbiol Lett,
2006, 261:181-6.
34) Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S; “Molecular basis of
resi stance to azole antifungals”; Trends Mol Med, 2002, 8:76-81.
35) Piddock LJ; “Multidrug-resistance efflux pumps-not just for resistance”; Nat Rev Microbiol, 2006, 4:629-36.
36) Tekaia F, Gordon SV, Garnier T, Brosch R, Barrel BG, Cole ST; “Analysis of
the proteome of Mycobacterium tuberculosis in silico”; Tuber Lung Dis, 1999,
79:329-42.
37) De Rossi E, Ainsa JA, Riccardi G; “Role of mycobacterial efflux transporters
in drug resi stance: an unresolved question”; FEMS Microbiol Rev, 2006,
30:36-52.
38) Pasca MR, Guglierame P, De Rossi E, Zara F, Riccardi G; “The mmpl7 gene
of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis”; Antimicrobial Agents Chemother, 2005,
